Novartis: Breast Neoplasms trials

The registry lists 199 Breast Neoplasms studies with Novartis as lead sponsor. 18 are open to participants now and 74 have results posted.

Early Phase 1 1Phase 1 51Phase 2 54Phase 3 48Phase 4 17No phase 43(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Real-world Outcomes Among Patients Treated With RibociclibCompletedNCT07148505
• A Study of Real-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast CancerCompletedNCT07086196
• An Indirect Treatment Comparison of the Effectiveness of Ribociclib Combined With Non-steroidal Aromatase Inhibitors vs. Tamoxifen for the Adjuvant Treatment of Premenopausal Women With Hormon Receptor-positive, HER2-negative Early Breast CancerCompletedNCT07072013
• A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or AlpelisibCompletedNCT06705504
• A Prospective Non-interventional Study to Evaluate Clinical Outcomes of Ribociclib Combined With Endocrine Therapy in Elderly Patients With HR+HER2 - Advanced Breast Cancer in Routine Clinical Practice in Russian FederationActive, not recruitingNCT06625333
• Observational Retrospective Study to Assess the Use of Ribociclib in Patients With HR+, HER2- Metastatic Breast Cancer Treated With ChemotherapyCompletedNCT06619704
• Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - REVEAL StudyCompletedNCT06463626
• A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line TreatmentCompletedNCT06311383
• A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.Active, not recruitingNCT06247995Phase 1/2
• A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the RussiaActive, not recruitingNCT06148506
• A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast CancerCompletedNCT06075758
• Biomarker Testing and Treatment Patterns Among Patients With PIK3CA Mutation in Advanced Breast CancerCompletedNCT05982886
• [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast CancerActive, not recruitingNCT05870579Phase 1
• A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of TherapyCompletedNCT05853432
• Phase IIIb Study of Ribociclib + ET in Early Breast CancerActive, not recruitingNCT05827081Phase 3
• Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in FranceActive, not recruitingNCT05697146
• Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast CancerCompletedNCT05569187
• Roll-over Study to Allow Continued Access to RibociclibActive, not recruitingNCT05161195Phase 4
• Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 InhibitorsCompletedNCT05153135
• A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 InhibitorsCompletedNCT05141240
• MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast CancerNo longer availableNCT05108740
• Survey Among Healthcare Professionals Treating Patients With Metastatic Breast Cancer in Selected European Countries to Evaluate Their Knowledge on Management of Hyperglycemia When Using AlpelisibCompletedNCT05073120
• Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.Active, not recruitingNCT05038735Phase 3
• Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-worldCompletedNCT05022342
• A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world SettingTerminatedNCT04967248
• A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in RussiaCompletedNCT04943497
• Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.TerminatedNCT04712721Early Phase 1
• Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast CancerActive, not recruitingNCT04544189Phase 2
• Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast CancerActive, not recruitingNCT04524000Phase 2
• Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA MutationActive, not recruitingNCT04208178Phase 3
• Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast CancerNo longer availableNCT03706573
• A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast CancerActive, not recruitingNCT03701334Phase 3
• Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast CancerWithdrawnNCT03081234Phase 3
• Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.CompletedNCT02947165Phase 1
• A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)CompletedNCT02900664Phase 1
• Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast CancersTerminatedNCT02734615Phase 1
• A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast CancerCompletedNCT02333370Phase 1
• Study of CLR457 Administered Orally in Adult Patients With Advanced Solid MalignanciesTerminatedNCT02189174Phase 1
• Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.CompletedNCT02154776Phase 1
• Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast CancerCompletedNCT02088684Phase 1
• Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic TumorsCompletedNCT02077933Phase 1
• A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast CancerCompletedNCT02058381Phase 1
• A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck CancerCompletedNCT02051751Phase 1
• Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast CancerCompletedNCT02023359
• Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)WithdrawnNCT01953536Phase 2
• Phase 1b Trial of BGJ398/BYL719 in Solid TumorsCompletedNCT01928459Phase 1
• Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast CancerActive, not recruitingNCT01872260Phase 1/2
• Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast CancerCompletedNCT01857193Phase 1
• Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.CompletedNCT01700270Phase 1
• 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast CancerCompletedNCT01626222Phase 3
• A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid TumorsCompletedNCT01626209Phase 1
• A Phase I Study of LFA102 in Japanese PatientsCompletedNCT01610050Phase 1
• A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric CancerCompletedNCT01598077Phase 1
• Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid TumorsCompletedNCT01576666Phase 1
• Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast CancerTerminatedNCT01495247Phase 1/2
• Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid TumorsCompletedNCT01482156Phase 1
• A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to TrastuzumabCompletedNCT01471847Phase 1
• Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast CancerCompletedNCT01338831Phase 1
• BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast CancerWithdrawnNCT01288092Phase 2
• Safety and Efficacy Study of Femara(Letrozole) as an Extended Adjuvant Treatment in Breast Cancer PatientsCompletedNCT01249456
• A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA GeneCompletedNCT01219699Phase 1
• Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)CompletedNCT01160094
• Safety of BKM120 Monotherapy in Advanced Solid Tumor PatientsCompletedNCT01068483Phase 1
• Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast CancerCompletedNCT00958971Phase 2
• Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer AgentsCompletedNCT00790816Phase 1
• A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast CancerCompletedNCT00788931Phase 1
• A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast CancerCompletedNCT00620594Phase 1
• A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast CancerCompletedNCT00600275Phase 1/2
• Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate MarkersCompletedNCT00535418Phase 2/3
• Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer PatientsCompletedNCT00526045Phase 1/2
• Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone MetastasesCompletedNCT00434447Phase 4
• Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone MetastasesCompletedNCT00434317Phase 4
• Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast CancerCompletedNCT00426530Phase 1
• Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior YearCompletedNCT00424983Phase 1
• Safety/Efficacy of Intravenous Zoledronic Acid When Added to Standard Therapies in Patients With Breast Cancer and Metastatic Bone LesionsTerminatedNCT00372710Phase 3
• Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast CancerCompletedNCT00372476Phase 4
• Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.CompletedNCT00367471Phase 1
• EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast CancerApproved for marketingNCT00338247
• Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast CancerCompletedNCT00334139Phase 4
• Letrozole in Metastatic Breast Cancer in Combination With ChemotherapyCompletedNCT00333047Phase 2/3
• Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast CancerCompletedNCT00332852Phase 3
• Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast CancerCompletedNCT00330317Phase 3
• Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast CancerCompletedNCT00329940Phase 3
• GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast CancerTerminatedNCT00251433Phase 1
• Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast CancerCompletedNCT00247663Phase 2
• Comparison Study of Letrozole Alone or Letrozole With Zoledronic Acid in Early Breast Cancer, Neoadjuvant TherapyCompletedNCT00247650Phase 2
• Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk AssessmentTerminatedNCT00241046Phase 4
• Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With LetrozoleCompletedNCT00237224Phase 4
• Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast CancerCompletedNCT00237211Phase 2
• Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen TreatmentCompletedNCT00237198Phase 2
• Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal WomenCompletedNCT00237133Phase 4
• Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic AcidCompletedNCT00172029Phase 4
• Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast CancerTerminatedNCT00171847Phase 4
• Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal WomenCompletedNCT00107016Phase 2
• EPO906 Therapy in Patients With Advanced Breast CancerCompletedNCT00035126Phase 2
• Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone LesionsCompletedNCT00029224Phase 4
• Letrozole in Treating Postmenopausal Women With Metastatic Breast CancerCompletedNCT00014638Phase 4
• Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast CancerCompletedNCT00006370Phase 2
• Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerCompletedNCT00006368Phase 1